Page last updated: 2024-09-02

sr 140333 and aprepitant

sr 140333 has been researched along with aprepitant in 1 studies

Compound Research Comparison

Studies
(sr 140333)
Trials
(sr 140333)
Recent Studies (post-2010)
(sr 140333)
Studies
(aprepitant)
Trials
(aprepitant)
Recent Studies (post-2010) (aprepitant)
236012769229521

Protein Interaction Comparison

ProteinTaxonomysr 140333 (IC50)aprepitant (IC50)
Cytochrome P450 3A4Homo sapiens (human)0.046
Substance-P receptorHomo sapiens (human)0.0002
Substance-P receptorMeriones unguiculatus (Mongolian gerbil)0.0001

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cao, Y; Cheng, X; Fu, C; Hong, X; Kang, J; Ma, J; Meng, Y; Shao, G; Shi, Y; Wang, L; Wang, X; Wang, Y; Yan, Z; Zhang, Q1

Other Studies

1 other study(ies) available for sr 140333 and aprepitant

ArticleYear
A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021, Volume: 8, Issue:21

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aprepitant; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Neurokinin-1 Receptor Antagonists; Piperidines; Proto-Oncogene Proteins c-myc; Quinuclidines; Signal Transduction; Survival Rate; Transplantation, Heterologous

2021